Gastrointestinal stromal tumor (GIST) is the most common soft tissue sarcoma [
[1]
]. The median age of GIST diagnosis is in the seventh decade, with a trend towards
increasing incidence with increasing age [
[2]
]. Tyrosine kinase inhibitor (TKI) use in both the localized and advanced setting
has significantly prolonged overall survival [
[3]
,
[4]
]. In patients with high-risk disease, following resection of their GIST, adjuvant
treatment with at least three years of imatinib is the standard of care [
- Casali P.G.
- Zalcberg J.
- Le Cesne A.
- et al.
Ten-year progression-free and overall survival in patients with unresectable or metastatic
GI stromal tumors: long-term analysis of the European Organisation for Research and
Treatment of Cancer, Italian sarcoma group, and Australasian gastrointestinal trials
group intergroup phase III randomized trial on imatinib at two dose levels.
J Clin Oncol. 2017; 35: 1713-1720
[3]
]. Patients with metastatic disease receive TKI therapy until disease progression
or patient stops tolerating therapy well. Imatinib was the first TKI approved in the
metastatic setting; sunitinib and regorafenib are second- and third-line options,
respectively. This study explores real world TKI practice patterns in the United States
(US) for treatment of GIST in individuals with private insurance coverage, evaluating
potential differences in TKI use between younger and older patients (aged 65 and above).Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Geriatric OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions.Cancer. 2012; 118: 5339-5348
- Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies.Cancer Epidemiol. 2016; 40: 39-46
- Survival outcomes associated with 3 years vs 1 year of adjuvant Imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up.JAMA Oncol. 2020; 6: 1241-1246
- Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels.J Clin Oncol. 2017; 35: 1713-1720
- Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - a retrospective multicentre study in a large cohort of GIST patients.Eur J Cancer. 2017; 86: 318-325
- Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications.Target Oncol. 2013; 8: 295-300
- Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).J Geriatr Oncol. 2018; 9: 520-525
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.The Lancet. 2006; 368: 1329-1338
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013; 381: 295-302
- Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).Acta Oncol. 2019; 58: 1648-1654
- Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer Centre.Clin Sarcoma Res. 2020; 10: 1
Article info
Publication history
Published online: January 28, 2023
Accepted:
January 19,
2023
Received in revised form:
November 3,
2022
Received:
September 12,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
